Cytokine & Growth Factor

Interplay of deubiquitinating enzymes and cytokines Publication date: Available online 8 June 2019 Source: Cytokine & Growth Factor Reviews Author(s): Bean Woo, Kwang-Hyun Baek Abstract Deubiquitinating enzymes (DUBs) are cysteine protease proteins that reverse the ubiquitination by removing ubiquitins from the target protein. With over 100 DUBs identified and categorized into at least 7 families, many DUBs interact with one or more cytokines, influencing cellular processes, such as antiviral responses, inflammatory responses, apoptosis, etc. While some DUBs influence cytokine pathway or production, some DUBs are cytokine-inducible. In this article, we summarize a list of DUBs, their interaction with cytokines, target proteins and mechanisms of action. Graphical abstract

Editorial Board Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s):

TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Antonella Mancusi, Maite Alvarez, Sara Piccinelli, Andrea Velardi, Antonio Pierini Abstract Tumor necrosis factor-α (TNF-α) signaling through TNF receptor 2 (TNFR2) plays a complex immune regulatory role in allogeneic hematopoietic cell transplantation (HCT). TNF-α is rapidly released in the circulation after the conditioning regimen with chemotherapy and/or radiotherapy. It activates the function of donor alloreactive T cells and donor Natural Killer cells and promotes graft versus tumor effects. However, donor alloreactive T cells also attack host tissues and cause graft versus host disease (GVHD), a life-threatening complication of HCT. Indeed, anti-TNF-α therapy has been used to treat steroid-refractory GVHD. Recent studies have highlighted another role for TNFR2 signaling, as it enhances the function of immune cells with suppressive properties, in particular CD4+Foxp3+ regulatory T cells (Tregs). Various clinical trials are employing Treg-based treatments to prevent or treat GVHD. The present review will discuss the effects of TNFR2 signaling in the setting of allogeneic HCT, the implications for the use of anti-TNF-α therapy to treat GVHD and the clinical perspectives of strategies that specifically target this pathway.

Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Wanvisa Udomsinprasert, Jiraphun Jittikoon, Sittisak Honsawek Abstract Interleukin-34 (IL-34), recently identified as a novel inflammatory cytokine and the second ligand for colony-stimulating factor-1 receptor, is known to play regulatory roles in the development, maintenance, and function of mononuclear phagocyte lineage cells – especially osteoclasts. Regarding its primary effect on osteoclasts, IL-34 has been shown to stimulate formation and activation of osteoclasts, which in turn magnifies osteoclasts-resorbing activity. In addition to its role in osteoclastogenesis, IL-34 has been implicated in inflammation of synovium via augmenting production of inflammatory mediators, in which altered IL-34 expression is regulated by pro-inflammatory cytokines responsible for cartilage degradation. Indeed, IL-34 has been documented to be highly expressed in inflamed synovium of rheumatoid arthritis (RA) and knee osteoarthritis (OA) patients, which are recognized as inflammatory arthritis. Furthermore, a number of clinical studies demonstrated that IL-34 levels were significantly increased in the circulation and synovial fluid of patients with RA and knee OA. Its levels were also found to be positively associated with disease severity – especially radiographic severity of both RA and knee OA patients. Interestingly, emerging evidence has accumulated that functional blockage of IL-34 with specific antibody can alleviate the severity of inflammatory arthritis. It is therefore reasonable to speculate that IL-34 may be developed as a potential biomarker and a new therapeutic candidate for inflammatory arthritis. To date, there are numerous studies showing IL-34 involvement and association with many aspects of inflammatory arthritis. Herein, this review aimed to summarize the recent findings regarding regulatory role of IL-34 in synovial inflammation-mediated cartilage destruction and update the current comprehensive knowledge on usefulness of IL-34-based treatment in inflammatory arthritis – particularly RA and knee OA. Graphical abstract

Mesenchymal stem cells immunomodulation: The road to IFN-γ licensing and the path ahead Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Amandda Évelin Silva- Carvalho, Marielly Reis Resende Sousa, Thuany Alencar-Silva, Juliana Lott Carvalho, Felipe Saldanha-Araujo Abstract Mesenchymal Stem Cells (MSCs) have gained prominence as an important tool in cell therapy, especially considering their capacity to control the immune system. Due to this property, the application of MSCs has been investigated for the treatment of several immune disorders, such as diabetes, rheumatoid arthritis, Crohn’s disease, systemic lupus erythematosus, and graft-versus-host-disease (GvHD). The application of MSCs to treat inflammatory diseases has led to impressive results. However, individual response to treatment is still heterogeneous, and the number of cells required to treat humans is very high. The possibility of increasing the immunosuppressive potential of MSCs is seen at this point as a promising alternative to overcome such limitations. One of the most exploited strategies for this purpose has been the licensing of MSCs prior to clinical application. In this review, we will discuss the mechanisms by which MSCs modulate the immune response and the main advances in the licensing of these cells, with a special focus on the use of interferon gamma (IFN-γ). Also, we will address the main challenges ahead before licensed MSCs are finally used successfully in clinical practice. Graphical abstract

Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Maebh Kelleher, Raminder Singh, Caitriona M. O’Driscoll, Silvia Melgar Abstract Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic intestinal inflammatory condition with increasing incidence worldwide and whose pathogenesis remains largely unknown. The collected evidence indicates that genetic, environmental and microbial factors and a dysregulated immune response are responsible for the disease. IBD has an early onset and long term sufferers present a higher risk of developing colitis associated cancer (CAC). The carcinoembryonic antigen-related adhesion molecules (CEACAM) are a subgroup of the CEA family, found in a range of different cell types and organs including epithelial cells in the intestine. They can act as intercellular adhesions molecules for e.g. bacteria and soluble antigens. CEACAMs are involved in a number of different processes including cell adhesion, proliferation, differentiation and tumour suppression. Some CEACAMs such as CEACAM1, CEACAM5 and CEACAM6 are highly associated with cancer and are even recognised as valid clinical markers for certain cancer forms. However, their role in IBD pathogenesis is less understood. The purpose of this review is to provide a comprehensive summary of published literature on CEACAMs and intestinal inflammation (IBD). The interactions between CEACAMs and bacteria adhesion in relation to IBD pathophysiology will be addressed and potential new therapeutic and diagnostic opportunities will be identified. Graphical abstract

Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Doreen M. Floss, Jürgen Scheller Abstract Cytokines control immune related events and are critically involved in a plethora of patho-physiological processes including autoimmunity and cancer development. Mutations which cause ligand-independent, constitutive activation of cytokine receptors are quite frequently found in diseases. Many constitutive-active cytokine receptor variants have been directly connected to disease development and mechanistically analyzed. Nature’s solutions to generate constitutive cytokine receptors has been recently adopted by synthetic cytokine receptor biology, with the goal to optimize immune therapeutics. Here, CAR T cell immmunotherapy represents the first example to combine synthetic biology with genetic engineering during therapy. Hence, constitutive-active cytokine receptors are therapeutic targets, but also emerging tools to improve or modulate immunotherapeutic strategies. This review gives a comprehensive insight into the field of naturally occurring and synthetic constitutive-active cytokine receptors. Graphical abstract

Role of JAK inhibitors and immune cells in transplantation Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Nicolas Sailliet, Carole Brosseau, Jean-Michel Robert, Sophie Brouard Abstract Immunosuppressive challenge after transplantation has dual objectives, namely, to efficiently inhibit immune populations involved in acute, chronic, humoral or cellular transplant rejection while minimizing the effect on immune integrity toward pathogens. The current immunosuppressive strategies show limited efficacy and remain associated with strong side effects, and thus, it is essential to develop new strategies. The use of Janus kinase (JAK) inhibitors is one of the new strategies focusing on cytokine pathways. Specifically, the first-generation JAK inhibitors (JAKis) showed low specificity toward the four known JAK molecules and did not exhibit better effects than calcineurin inhibitors, which constitute the standard treatment posttransplantation. However, because the new generation of JAKis present higher specificity, we are gaining further insights on the response of cells to these inhibitions. This review focuses on the impact of JAKis on different immune cell subsets, focusing on their role in transplantation.

Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Hongxiang Lu, Zhenzhen Zhang, Prince Amoah Barnie, Zhaoliang Su Abstract High mobility group box 1 (HMGB1) is constitutively expressed by many cells. In cells, HMGB1 is a transcription factor or transcription enhancer that is involved in nucleosome sliding, DNA repair, V(D)J recombination, telomere homeostasis, autophagy and viral sensing. HMGB1 can also be secreted or released by stressed cells and serves as an alarmin, cytokine or growth factor to activate the immune response. This protein facilitates CD4+ T cell differentiation and tissue repair through binding with its receptors, including toll-like receptors (TLRs) and the receptor for advanced glycation end-products (RAGE). Recent works have established that HMGB1 plays many vital functions in cardiac inflammatory injury, cardiac regeneration and remodelling. The present review addresses the novel role of HMGB1 in secretion and cardiomyocyte senescence and in the dual faced roles of HMGB1 in cardiac inflammatory injury, inflammatory resolution and cardiac regeneration and remodelling following cardiac injury. Graphical abstract

Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases Publication date: June 2019 Source: Cytokine & Growth Factor Reviews, Volume 47 Author(s): Hemanth Kumar Kandikattu, Sathisha Upparahalli Venkateshaiah, Anil Mishra Abstract Eosinophils are circulating granulocytes that have pleiotropic effects in response to inflammatory signals in the body. In response to allergens or pathogens, exposure eosinophils are recruited in various organs that execute pathological immune responses. IL-5 plays a key role in the differentiation, development, and survival of eosinophils. Eosinophils are involved in a variety of allergic diseases including asthma, dermatitis and various gastrointestinal disorders (EGID). IL-5 signal transduction involves JAK-STAT-p38MAPK-NFκB activation and executes extracellular matrix remodeling, EMT transition and immune responses in allergic diseases. IL-18 is a classical cytokine also involved in immune responses and has a critical role in inflammasome pathway. We recently identified the IL-18 role in the generation, transformation, and maturation of (CD101+CD274+) pathogenic eosinophils. In, addition, several other cytokines like IL-2, IL-4, IL-13, IL-21, and IL-33 also contribute in advancing eosinophils associated immune responses in innate and adaptive immunity. This review discusses with a major focus (1) Eosinophils and its constituents, (2) Role of IL-5 and IL-18 in eosinophils development, transformation, maturation, signal transduction of IL-5 and IL-18, (3) The role of eosinophils in allergic disorders and (4) The role of several other associated cytokines in promoting eosinophils mediated allergic diseases. Graphical abstract